Related Experiment Video
Updated: Aug 15, 2026
Curcuminoid-Mediated Antimicrobial Photodynamic Therapy on a Murine Model of Oral Candidiasis
Published on: October 27, 2023
Chemically modified curcumin in periodontal therapy: a scoping review
Vishala Bhargavi Chilukuri1, Rupali Agnihotri2, Deepa G Kamath3
1Department of Periodontology, Manipal College of Dental Sciences, Manipal Academy of Higher Education, Manipal, India.
Aims/Objectives:
Periodontitis, a multifactorial chronic inflammatory disease that destroys the supporting structures of the teeth, is conventionally managed with treatments focusing on biofilm removal; however, these therapies do not fully address the dysregulated host response central to disease progression. To address this, chemically modified curcumin (CMC) analogues have been developed by modifying curcumin, a derivative of Curcuma longa, a host-modulating agent with potent anti-inflammatory and antioxidant properties. Recently, CMCs have been used to manage periodontitis. This scoping review systematically maps the available evidence on the therapeutic potential of CMCs and their analogues in managing periodontal disease.
Methods:
A comprehensive literature search in online databases (PubMed, EMBASE, Scopus and Web of Science) using the keywords "chemically modified curcumin" AND "periodontitis" yielded 76 results. Among them, 15 original research studies that evaluated the effects of CMC analogues on periodontitis were reviewed according to the PRISMA-ScR guidelines.
Results:
CMC2.24 was the most common analogue studied, followed by CMC 2.5, the mono-carbonyl analogue of curcumin (e.g., 1A) and iron-curcumin nanoparticles. They produced consistent anti-inflammatory and bone-protective effects across multiple in vitro, ex vivo and animal models. They suppressed the pathologically elevated MMP-9 and pro-inflammatory cytokines, including IL-1β, TNF-α and IL-6. Furthermore, they enhanced pro-resolving mediators, such as Resolvin D1. CMCs were superior to traditional curcumin, owing to their improved stability and bioavailability.
Discussion:
Analysis of the extracted data from the included studies revealed that the CMC analogues effectively reduced excessive inflammation, tissue degradation and dysregulated immune response in periodontitis.
Conclusion:
CMC2.24 was a promising host-modulating agent in periodontal therapy. However, the results are mainly derived from preclinical studies and further human clinical trials are required to apply CMCs into everyday practice.
